Patents
Literature
17 results about "Quantitative proteomics" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Quantitative proteomics is an analytical chemistry technique for determining the amount of proteins in a sample. The methods for protein identification are identical to those used in general (i.e. qualitative) proteomics, but include quantification as an additional dimension. Rather than just providing lists of proteins identified in a certain sample, quantitative proteomics yields information about the physiological differences between two biological samples. For example, this approach can be used to compare samples from healthy and diseased patients. Quantitative proteomics is mainly performed by two-dimensional gel electrophoresis (2-DE) or mass spectrometry (MS). However, a recent developed method of quantitative dot blot (QDB) analysis is able to measure both the absolute and relative quantity of an individual proteins in the sample in high throughput format, thus open a new direction for proteomic research. In contrast to 2-DE, which requires MS for the downstream protein identification, MS technology can identify and quantify the changes.
Cloning and application of rice bacterial blight resistant gene LTPL160
The invention relates to a DNA (Deoxyribose Nucleic Acid) for regulating and controlling a resistance gene LTPL160 of rice bacterial blight and breeding utilization of a protein of the DNA. According to the invention, the gene OsLTPL160 for regulating and controlling the resistance of the rice bacterial leaf blight is cloned by virtue of a non-gel quantitative proteomics analysis and transcription analysis method. The OsLTPL160 knockout and overexpression material is obtained by adopting a gene editing and transgenic technology. The OsLTPL160 is knocked out, so that the bacterial blight resistance of the rice is remarkably improved; and overexpression of the OsLTPL160 obviously reduces the resistance of the bacterial blight of the rice. The cloning of the OsLTPL160 gene and the construction of the material provide material and technical support for the bacterial blight resistance of the rice.
Owner:JIANGSU ACAD OF AGRI SCI +1
Protein marker for lung metastasis of primary liver cancer and application of protein marker
The invention belongs to the field of biological medicine, and particularly relates to a protein marker for lung metastasis of primary liver cancer and application of the protein marker. The invention discloses a protein marker for lung metastasis of primary liver cancer. The protein marker is selected from at least one of rs2 protein, rcsd1 protein, rbbp9 protein, prl6a1 protein, ubxn4 protein and mospd2 protein. According to the invention, mass spectrometry is carried out by using an HPLC-MS / MS mass spectrometry system and an unlabeled quantitative proteomics method; and then searching mass spectrum data by utilizing a non-limited amino acid protein modification analysis method, and verifying whether differential protein substances have significance or not according to P-value, so as to finally obtain six proteins with significant difference, namely, the rs2 protein, the rcsd1 protein, the rbbp9 protein, the prl6a1 protein, the ubxn4 protein and the mospd2 protein. The protein marker provided by the invention has higher sensitivity and specificity, and the combination of the six proteins has better detection efficacy.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE
Marker combination, kit thereof and application of marker combination in prediction of diabetic peripheral neuropathy
The invention discloses a marker combination, a kit thereof and application of the marker combination to prediction of diabetic peripheral neuropathy, the marker combination comprises human angiotensin (ANG), human vascular endothelial cell adhesion molecule 1 (VCAM1) and human mannan binding lectin serine peptide 1 (MASP1), TMT quantitative proteomics and PRM targeted proteomics are adopted, and the marker combination is used for detecting diabetic peripheral neuropathy. A technology combination strategy of an ELISA experiment is adopted, and key differential expression proteins such as MASP1, VCAM1 and ANG in serum exosomes of patients with diabetic peripheral neuropathy are systematically screened and verified. By establishing a multi-model machine learning diagnosis system based on logistic regression, a support vector machine and a naive Bayes algorithm, simple and rapid identification of diabetic peripheral neuropathy patients is realized, and a new experimental basis is provided for clarification of a molecular regulation network of diabetic peripheral neuropathy; more importantly, a rapid screening tool with clinical application potential is developed.
Owner:SHANGHAI TENTH PEOPLES HOSPITAL
Serum protein marker for ossification of ligamentum flavum and application of serum protein marker
The invention relates to the technical field of biomedicine, in particular to a serum protein marker for ossification of ligamentum flavum and application of the serum protein marker. The serum protein marker comprises erythrocyte glucose phosphate isomerase and / or dystrophin associated glycoprotein 1. According to the method, a data-independent quantitative proteomics strategy is utilized to compare a normal healthy control (a patient who does not suffer from ligamentum flavum ossification and needs spinal surgery to take ligamentum flavum tissues) with a ligamentum flavum ossification patient; it is found that ligamentum flavum ossification-related proteins, namely erythrocyte glucose phosphate isomerase (GPI) and dystrophy protein-related glycoprotein 1 (DAG1), with the obviously-changed expression quantity in tissue are beneficial to diagnosis of patients with ligamentum flavum ossification and provide effective targets for development of treatment methods of the ligamentum flavum ossification.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL
Single cell level proteomics analysis system and analysis method for mass spectrum system
PendingCN121431702AComponent separationBiological testingEnzymatic digestionMass Spectrometry-Mass Spectrometry
The invention belongs to a proteomics analysis technology in the technical field of biology, and particularly relates to a single-cell-level proteomics analysis system and analysis method for a mass spectrum system. The analysis system comprises a sample pretreatment optimization subsystem and a chromatography-mass spectrometry acquisition optimization subsystem, the purpose of the sample pretreatment optimization subsystem is to efficiently and stably prepare a peptide fragment mixture capable of being used on a mass spectrum machine from a trace cell sample. The sample loss is reduced by improving the protein extraction and enzymolysis efficiency of trace (nanogram-level) and single-cell-level protein samples. By optimizing mass spectrum data acquisition parameters, the identification depth and quantity of proteins are improved while the analysis time is shortened (the flux is improved). By adopting the analysis system disclosed by the invention, the accuracy and reproducibility of quantitative analysis of the micro sample proteome can be remarkably improved.
Owner:ZHEJIANG UNIV OF TECH +1
A method for screening a shikonin acting target point based on LIP-MS technology
ActiveCN119395303Bimprove accuracyhigh sensitivityComponent separationBiological testingPeptide FingerprintsProtein target
The application discloses a method for screening shikonin acting target points based on LIP-MS technology, and relates to the technical field of medicines, and has the technical features that the application adopts a widely specific protease to perform limited enzymolysis on a protein sample, utilizes the characteristic that drug and target protein combination can improve the conformation stability of the combination region peptide segment, further uses trypsin to perform secondary enzymolysis, collects a peptide fingerprint by using quantitative proteomics technology, analyzes and compares the changes of the peptide fingerprints of a control group and a drug treatment group, screens out the specificity of the 'conformational retention peptide segment' after drug treatment, identifies the target protein information corresponding to the peptide segment by database matching, compared with the traditional DARTS method, the non-labeled drug target analysis based on the peptide fingerprint changes the detection object from the protein into the peptide segment, and is expected to characterize the low-affinity multi-target drug and protein interaction, low-abundance protein, large molecular weight protein local conformation change information, so as to improve the accuracy and sensitivity of target analysis.
Owner:THE NAVAL MEDICAL UNIV OF PLA
Method for analyzing target spot of cyclosporine for treating aplastic anemia
The invention relates to the technical field of bioinformatics, and provides an analysis method for treating aplastic anemia (AA) targets by cyclosporine, which comprises the following steps: collecting plasma samples from a preliminary diagnosis patient, a disease stable period patient and a healthy control group; the method comprises the following steps: based on a DIA quantitative proteomics method, analyzing proteins in a plasma sample by adopting a liquid chromatography-mass spectrometer (LC-MS) method, and screening differential expression proteins; carrying out enrichment analysis and pathway analysis on the differential expression protein; verifying the expression levels of the differential expression proteins in different groups by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) method to obtain key differential expression proteins; a molecular docking technology is adopted to verify the binding capacity of cyclosporine and the differential expression protein, and the potential of the key differential expression protein as a therapeutic target is determined. Different differential proteins of AA patients and healthy people before and after treatment are successfully obtained, an experimental basis is provided for exploring a mechanism for treating AA by cyclosporine, and possibility is provided for searching a new treatment target.
Owner:YIXING PEOPLES HOSPITAL
Drug target of tribulus terrestris extract for treating pulmonary fibrosis as well as screening method and application of drug target
PendingCN120733072ACompounds screening/testingMicrobiological testing/measurementProtein targetPhosphorylation
The invention relates to the technical field of pharmacological research, in particular to a drug target of tribulus terrestris extract for treating pulmonary fibrosis as well as a screening method and application of the drug target. According to the invention, the effective treatment effect of TED on PF is determined through pharmacodynamic research. The SCD2 protein is preliminarily screened as the target protein by using a 4D-SmartDIA quantitative proteomics technology, the protein expression level proves that the SCD2 expression and phosphorylation level in the mouse lung tissue after TED treatment are obviously increased, and the interaction between SCD2 and phosphorylation is investigated and determined. Therefore, the SCD2 can be used as a drug target for predicting the treatment of the TED on the PF. And a basis is provided for development of PF treatment drugs.
Owner:BAOTOU MEDICAL COLLEGE OF INNER MONGOLIA UNIV OF SCI & TECH
Method for detecting protein having changes in energy state, or affinity of ligand to protein
Disclosed in the present invention is a method for detecting a protein having changes in an energy state, and affinity of a ligand to a protein. Specifically, after the energy state of a protein changes, the tolerance to enzyme cleavage destruction changes, the structure of the protein in a low-energy state is also destroyed under a non-denaturation condition by using a large amount of enzymes, and a small peptide fragment which has a molecular weight of less than 5 KDa and can be directly used for bottom-top mass spectrometry analysis is directly generated. The method has extremely high sensitivity, and quantitative proteomics is used to find enzyme cleavage differential peptide fragments, and proteins to which the differential peptide fragments belong and the positions in the proteins are analyzed, so that a protein having changes in an energy state, and a change region can be determined in the whole proteome range. If the energy state of the protein changes due to addition of a ligand, the method can determine a binding protein and a binding region of the ligand; and the output of a quantitative result on the peptide fragment level further enables the method to determine the local affinity of binding of the ligand to the protein.
Owner:DALIAN INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES
18 beta-glycyrrhetinic acid derivative containing diene structure fragment as well as preparation method and application of 18 beta-glycyrrhetinic acid derivative
The invention discloses a 18 beta-glycyrrhetinic acid derivative containing a diene structure fragment as shown in a general formula I and a preparation method and application thereof, and belongs to the technical field of medicines, the compound can effectively degrade HDAC3, and further mechanism studies (including Western Blot and quantitative proteomics) prove that a representative compound can effectively degrade the HDAC3 by inducing the degradation of the HDAC3 through specificity. Further, an NLRP3 inflammasome pathway is inhibited, and finally, maturation and secretion of downstream inflammatory factors IL-1beta and caspase-1 are blocked, so that a remarkable anti-inflammatory effect is achieved. A mouse acute shock and colitis model further verifies the excellent anti-inflammatory activity of the compound in vivo. The invention not only provides a novel HDAC3 degradation agent with good activity, but also lays a solid material and theoretical foundation for deep development of anti-inflammatory drugs based on the 18 beta-glycyrrhetinic acid structure.
Owner:SHENYANG PHARMA UNIV
Use of a combination of plasma proteins in screening for pancreatic cancer
PendingCN122109536AMedical data miningComponent separationPancreas CancersMass Spectrometry-Mass Spectrometry
The application belongs to the technical field of proteomics and clinical disease screening, and relates to application of a combination of plasma proteins in screening of pancreatic cancer. The application is based on mass spectrometry quantitative proteomics technology, screens and determines a marker combination composed of four plasma proteins of GCLC, ALAD, HAGH and SORD, and comprehensively analyzes relative abundance of the marker combination through a binary Logistic regression model to distinguish pancreatic cancer patients from healthy people. Experimental results show that the protein combination has high sensitivity, specificity and area under curve (AUC) in a screening set and an independent verification set, and has good stability and repeatability. The method has the advantages of non-invasiveness, feasible operation and applicability to population screening by taking plasma as a detection sample, and can provide a new technical means for early screening of pancreatic cancer.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES +2
Pseudo MS3 Strategy Employing PTR for Labelled Quantitative Proteomics
PendingUS20250285850A1Particle spectrometer methodsSpecific reaction combinationsChemical physicsMass Spectrometry-Mass Spectrometry
In one aspect, a method of performing mass spectrometry is disclosed, which includes selecting a precursor ion having an m / z ratio in a range of interest from among a plurality of ions, identifying a charge state of the selected precursor ion, e.g., based on distribution of mass peaks associated with different isotopes in a mass spectrum. The charge state of the selected precursor ion can be reduced to generate a respective charge-reduced ion at a known m / z ratio. The charge-reduced ion can be subjected to fragmentation to generate a plurality of product ions (which are herein also referred to as fragment ions). A mass analysis of the product ions can then be performed.
Owner:DH TECH DEVMENT PTE
Isoprene-like pyrophosphate photoaffinity probe as well as preparation method and application thereof
The invention belongs to the technical field of biological detection and analysis, and particularly relates to an isoprenyl pyrophosphate photoaffinity probe as well as a preparation method and application thereof. Specifically, on the basis that the structure of isoprenyl pyrophosphate is connected with small photoaffinity side chain modification, a novel small-molecule active probe for detecting the isoprenyl pyrophosphate binding protein is developed; the probe can be used for effectively marking the isoprenoid pyrophosphate binding protein in a cell lysis solution for fluorescent gel imaging analysis and high-flux proteomics analysis, and the isoprenoid interaction protein is identified by combining quantitative proteomics analysis; the probe can also be used for marking living cells and corresponding fluorescence imaging analysis and protein spectrum analysis, so that the probe has good practical application value.
Owner:SHANDONG UNIV
Method for screening exosome biomarkers derived from drug-loaded breast tumor stem cells
The invention belongs to the technical field of biomedicine, and discloses a method for screening a drug-loaded breast tumor stem cell-derived exosome biomarker, which is characterized in that: quantitative proteomics is combined with biosignal analysis to screen exosome key proteins with significant difference in breast cancer; the biological function and regulation mechanism of the exosome key protein in drug resistance of breast tumor stem cells are determined through clinical level and cellular level. Aiming at the difficult problem of drug resistance specificity diagnosis and treatment of breast tumor, research is planned to be carried out in the field of tumor stem cell and exosome hotspot scientific research, and key proteins with significant difference in the breast tumor stem cell source exosome are screened through quantitative proteomics, protein expression profiles and databases; clinical sample detection and in-vivo and in-vitro experiments are combined to deeply discuss the regulation mechanism of the key protein in breast tumor drug resistance, it is clear that the key protein possibly becomes a biomarker for early diagnosis, curative effect evaluation and prognosis judgment of breast cancer, and help is better provided for precise targeted treatment of breast tumors.
Owner:NINGXIA MEDICAL UNIVERSITY GENERAL HOSPITAL
Digital protein quantification
ActiveUS12467931B2Sequential/parallel process reactionsLibrary tagsBioinformaticsQuantitative proteomics
Methods and compositions are described for single cell resolution, quantitative proteomic analysis using high throughput sequencing.
Owner:BIO RAD LABORATORIES INC +1
Comprehensive evaluation method for efficacy quality of traditional Chinese medicine compound and application of comprehensive evaluation method
The invention provides a traditional Chinese medicine compound efficacy quality comprehensive evaluation method and application thereof, the comprehensive evaluation method adopts a targeted quantitative proteomics technology to quantify an anti-myocardial ischemia biomarker of a Guanxintong capsule, and quantitative analysis is carried out on the anti-myocardial ischemia biological effect of the Guanxintong capsule from the cellular level. According to the invention, the accurate quantitative correlation between the Q-marker of the Guanxinshutong capsule and the anti-myocardial ischemia biomarker based on the BP neural network is constructed, the overall quality evaluation system of the Guanxinshutong capsule based on the Q-marker is established, the quantitative correlation with the overall biological effect is realized, the quality standard of a high-quality product is established, and a reference is provided for the quality and efficacy evaluation of a traditional Chinese medicine compound.
Owner:SHANXI BUCHANG PHARMA CO LTD
Low energy cleavable mass tag for quantitative proteomics
The present invention relates to a compound which comprises or consists of (a) a reactive moiety, said reactive moiety being capable of reacting with a functional group of a peptide to form a covalent bond; and covalently joined thereto (b) a moiety which fragments in the mass spectrometer (i) at an energy below the energy required for fragmenting peptides and / or a higher conversion rate than peptides; and (ii) at said energy according to (i) and when coupled to a peptide via said reactive group, at a single site within said compound coupled to a peptide, to yield a first moiety and a second moiety, said second moiety being coupled to said peptide.
Owner:BRUKER SWITZERLAND AG